Continuing Legal Education (CLE)
AIPLA Rapid Response Webinar: Arthrex and its Impact on Your Practice
July 7, 2021 12:00 PM to 1:15 PM
Member-benefit exclusive! CLE credit is available on a limited basis.
On June 21, 2021, in a 5-4 decision, the U.S. Supreme Court issued its decision in United States v. Arthrex, Inc., Nos. 19-1434, 19-1452, and 19-1458, reversing and vacating the Federal Circuit decision. Chief Justice Roberts issued the majority decision, holding that the unreviewable authority wielded by Administrative Patent Judges (APJs) during inter partes review is constitutionally incompatible with their appointment by the Secretary of Commerce to an inferior office. The majority found that “35 U. S. C. § 6(c) is unenforceable as applied to the Director insofar as it prevents the Director from reviewing the decisions of the PTAB on his own.” In this case, the Court determined that an appropriate remedy is a remand to the Acting Director to decide whether to rehear the petition filed by Smith & Nephew. Additionally, the Court stated that Arthrex is not entitled to a hearing before a new panel of APJs. The Court’s full decision may be found here.
Please join our expert panel, including representatives for each of the parties to the case, to help us understand the Supreme Court’s decision, its implications and what you need to know for your practice. The panel will be moderated by AIPLA Sophie Wang, who authored AIPLA’s amicus brief, and the panelists include Malcolm Stewart, Mark Perry, and Robert Kry. Join in on July 7, 2021, from 12-1:15 PM ET, for an informative discussion.
This event is FREE to AIPLA members who are not requesting CLE.
Limited CLE is available and standard webinar pricing applies to those requesting CLE for the listed states.
CLE is included for our All Access Pass holders and Corporate Subscribers for the states listed below.
Pricing is for those requesting CLE in the states listed below.
Solo Practice/Small Firm Members: $65
CLE credit for this webinar is only available for the following states:
- Alaska
- California
- New Hampshire
- New Mexico
- New York
- New Jersey
- Pennsylvania
- Vermont
ATTENTION attorneys in Pennsylvania:
This state mandate attorneys can only view a webinar independently at their own computer to receive CLE credit. Multiple attendees prohibited.
Cancellation Policy:
To get full refund, registrant must request refund five (5) days prior to live event. If less than five (5) days, registrant is transferred to product.
System requirements:
Webinar access is compatible with any Windows 7 or later computer, Android OS devices, or Apple/iOS devices. Check system compatibility here.
Accessibility for hearing impaired:
AIPLA’s webinars are available and accessible to individuals who are hearing impaired. If anyone at your location would like to know more about accommodations, please contact cle@aipla.org. We ask that you let us know at least 7 business days out from the webinar, to ensure that we can identify and deploy the solution that best fits our registrants needs.
Disclaimer: AIPLA is a nonprofit national bar association. The sole purpose of this CLE program is to provide educational and informational content. AIPLA does not provide legal services or advice. The opinions, views and other statements expressed by contributors to this CLE program are solely those of the contributors. These opinions, views and statements of the contributors do not necessarily represent those of AIPLA and should not be construed as such.
News
-
Supreme Court Issues Unanimous Decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
June 4, 2026
On June 4, 2026, the Supreme Court issued a unanimous decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. While the Court reaffirmed existing law on pleading standards, it reversed the Federal Circuit’s decision that had focused on how relevant statements could be understood by medical providers as instructions to infringe. The amicus brief filed by AIPLA on March 27, 2026, advocated for affirmance and cautioned the Court not to change the patent infringement pleading standard or adopt any categorical exemption from inducement for a particular industry. -
AIPLA Submits Comments to the USPTO on 2026 Supplemental GUI Guidance
May 15, 2026
Arlington, VA. May 12, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments to the USPTO on its Supplemental Guidance for Examination of Design Patent Applications Related to Computer-Generated Interfaces and Icons, issued on March 13, 2026. -
AIPLA Comments on the Copyright Office's Proposed Fee Schedule Adjustment
May 8, 2026
Arlington, VA. May 1, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments in response to the U.S. Copyright Office’s Notice of Proposed Rulemaking on adjustments to its fee schedule. -
AIPLA Submits Comments on the Enlarged Board of Appeal’s 11 Preliminary Opinion in G 1/25
May 1, 2026
Arlington, VA. April 17, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments on the Enlarged Board of Appeal’s 11 March 2026 preliminary opinion in G 1/25, addressing whether patent descriptions must be adapted following claim amendments. -
AIPLA Files Amicus Brief in Range of Motion Products, LLC v. Armaid Company Inc.
April 20, 2026
Arlington, VA — April 17, 2026 — The American Intellectual Property Law Association (AIPLA) filed an amicus curiae brief with the U.S. Court of Appeals for the Federal Circuit in Range of Motion Products, LLC v. Armaid Company Inc., No. 23-2427, supporting rehearing and rehearing en banc. AIPLA urges the Court to restore clarity to design patent law by (1) reaffirming that Gorham v. White (1871) provides the sole governing test for infringement and forecloses any separate “plainly dissimilar” threshold, and (2) confirming that claim construction may not be used to exclude any visual portions of the overall claimed design.